Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.


Related Content

Signs Point To Banner Year For Novel Approvals In 2014
New Drugs In 2013 Show A Virtuous Cycle: First-Cycle Approvals Up, Review Times Down
Protein Sciences To Begin Selling Novel Flu Vaccine; Flublok Has Virus-Free Appeal
New Biologics Total Seven In 2007, But Only Four Will See Market


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts